Longevity for Women: The Evidence-Based Guide to the Female-Specific Aging Timeline
Women in the United States live longer than men, by 4.9 years in 2024 (CDC National Center for Health Statistics), yet they report more illness late in life.10 The menopause transition is a time of accelerating cardiovascular risk,5 and this guide covers that and other parts of the female-specific aging timeline.
- Women typically develop coronary heart disease several years later than men, and their risk rises notably after menopause; long-term studies document adverse changes in body composition, lipids and vascular health across the menopause transition.5
- Midlife is a good time to act: an American Heart Association statement calls it a critical window for early prevention,5 and the 2022 Menopause Society statement finds hormone therapy's benefit-risk ratio favourable under 60 or within 10 years of menopause for women without contraindications.11
- Breast cancer risk is the primary concern that has historically deterred HRT use in women. The evidence: in the WHI trials, estrogen alone lowered breast cancer incidence, while estrogen plus a synthetic progestin raised it;6 observational data show some added risk with most types and with longer use, and evidence for micronized progesterone is observational.7 Transdermal estradiol avoids the clot risk of oral estrogen,8 but in randomized trials hormone therapy neither improved nor harmed cognition.9
- The USPSTF recommends osteoporosis screening for women 65 and older and for younger postmenopausal women with risk factors (USPSTF).
- Most autoimmune diseases affect women more often than men.4
Female aging follows its own course, shaped by the hormonal changes of midlife. Women typically develop coronary heart disease several years later than men, with risk rising after menopause;5 most autoimmune diseases affect women more often than men;4 and women report more illness late in life despite living longer.10
The Menopause Transition: The Central Biological Event
Longitudinal studies that followed women through menopause have separated the effects of chronological aging from those of ovarian aging. They document distinct patterns of sex hormone change and adverse changes in body composition, lipids and lipoproteins, and vascular health across the transition.5
The HRT Evidence Revisited for Women's Longevity
Our HRT article reviews the evidence in detail. In the overall WHI population, whose average age was 63, neither estrogen-progestin nor estrogen-only therapy prevented coronary heart disease or produced a favourable balance of benefits and risks.3 In the WHI trials, estrogen alone lowered breast cancer incidence and mortality in women who had had a hysterectomy, while estrogen plus a synthetic progestin raised incidence;6 a 2019 meta-analysis found added breast cancer risk with every systemic type, rising with duration of use.7 In UK data, transdermal therapy was not associated with blood clots, while oral therapy was (adjusted odds ratio 1.58).8 In a randomized trial of 567 women, estradiol neither helped nor harmed memory or thinking, whether started within 6 years of menopause or 10 or more years after.9 Some authors argue that hormone therapy should be part of a general prevention strategy for women at the onset of menopause;2 the 2022 Menopause Society statement takes an individualized view, with the most favourable benefit-risk ratio under 60 or within 10 years of menopause.11
Cardiovascular Risk: The Post-Menopause Acceleration
Before menopause, women have lower cardiovascular disease risk than men of the same age and typically develop coronary heart disease several years later; the menopause transition is a time of accelerating cardiovascular risk.5 The American Heart Association statement therefore stresses monitoring women's health in midlife and starting prevention early.5 Awareness that heart disease is the leading cause of death in women nearly doubled between 1997 and 2009, while the cardiovascular death rate fell by nearly half over the same period.1 Our Life's Essential 8 calculator scores the main cardiovascular measures in one place.
Alzheimer's Disease in Women
One hypothesis links Alzheimer's disease in women to the loss of estrogen at menopause and suggests that hormone therapy started early could protect the brain. In a randomized trial designed to test that timing idea, estradiol started within 6 years of menopause did not affect memory or thinking differently from estradiol started 10 or more years later, and it neither helped nor harmed cognition.9
Autoimmune Disease: The Underappreciated Female Burden
For most autoimmune diseases, women are affected more often than men, and researchers consider gender a significant influence on how these diseases develop.4
Put this research into practice: What Should I Test Next?
References
- 1Mosca L, et al. "Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes." Circulation. 2011;124(19):2145-54. PubMed · DOI
- 2Lobo RA, et al. "Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause." Atherosclerosis. 2016;254:282-290. PubMed · DOI
- 3Manson JE, et al. "The Women's Health Initiative trials of menopausal hormone therapy: lessons learned." Menopause. 2020;27(8):918-928. PubMed · DOI
- 4Ngo ST, et al. "Gender differences in autoimmune disease." Front Neuroendocrinol. 2014;35(3):347-69. PubMed · DOI
- 5El Khoudary SR, et al. "Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association." Circulation. 2020;142(25):e506-e532. PubMed · DOI
- 6Chlebowski RT, et al. "Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials." JAMA. 2020;324(4):369-380. PubMed · DOI
- 7Collaborative Group on Hormonal Factors in Breast Cancer. "Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence." Lancet. 2019;394(10204):1159-1168. PubMed · DOI
- 8Vinogradova Y, et al. "Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases." BMJ. 2019;364:k4810. PubMed · DOI
- 9Henderson VW, et al. "Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis." Neurology. 2016;87(7):699-708. PubMed · DOI
- 10Austad SN, Fischer KE. "Sex Differences in Lifespan." Cell Metab. 2016;23(6):1022-1033. PubMed · DOI
- 11“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. "The 2022 hormone therapy position statement of The North American Menopause Society." Menopause. 2022;29(7):767-794. PubMed · DOI
